- Home
- LILA vs MLYS Comparison
LILA vs MLYS Comparison
Compare LILA & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILA
- MLYS
- Stock Information
- Founded
- LILA 2017
- MLYS 2019
- Country
- LILA Bermuda
- MLYS United States
- Employees
- LILA N/A
- MLYS N/A
- Industry
- LILA Cable & Other Pay Television Services
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- LILA Telecommunications
- MLYS Health Care
- Exchange
- LILA Nasdaq
- MLYS Nasdaq
- Market Cap
- LILA 1.1B
- MLYS 1.0B
- IPO Year
- LILA N/A
- MLYS 2023
- Fundamental
- Price
- LILA $4.91
- MLYS $15.58
- Analyst Decision
- LILA Buy
- MLYS Strong Buy
- Analyst Count
- LILA 2
- MLYS 3
- Target Price
- LILA $7.90
- MLYS $33.00
- AVG Volume (30 Days)
- LILA 729.9K
- MLYS 866.7K
- Earning Date
- LILA 05-07-2025
- MLYS 05-12-2025
- Dividend Yield
- LILA N/A
- MLYS N/A
- EPS Growth
- LILA N/A
- MLYS N/A
- EPS
- LILA N/A
- MLYS N/A
- Revenue
- LILA $4,441,000,000.00
- MLYS N/A
- Revenue This Year
- LILA $3.30
- MLYS N/A
- Revenue Next Year
- LILA $3.11
- MLYS N/A
- P/E Ratio
- LILA N/A
- MLYS N/A
- Revenue Growth
- LILA N/A
- MLYS N/A
- 52 Week Low
- LILA $4.26
- MLYS $8.24
- 52 Week High
- LILA $10.82
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- LILA 42.45
- MLYS 54.41
- Support Level
- LILA $4.83
- MLYS $15.45
- Resistance Level
- LILA $5.18
- MLYS $16.11
- Average True Range (ATR)
- LILA 0.24
- MLYS 0.96
- MACD
- LILA 0.02
- MLYS -0.05
- Stochastic Oscillator
- LILA 52.29
- MLYS 51.56
About LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.